AI-generated analysis. Always verify with the original filing.
Elite Pharmaceuticals, Inc. reported third quarter fiscal year 2026 financial results for the three months ended December 31, 2025, with consolidated revenues of $31.6 million and income from operations of $9.0 million, and net income of $18.6 million. The company filed its Form 10-Q and will host a conference call on February 18, 2026, to discuss results and business updates.
Event Type
Disclosure
Mandatory
Variant
8-K
, “Results of Operations and Financial Condition,” Item 7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such,
Regulation FD Disclosure. The information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on F
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated February 17, 2026 104 Cover Page Interactive Data File (embedd
| Metric | Value | Basis |
|---|---|---|
| Revenue | $31.60 | |
| Income from operations | $9.00 | |
| Net income | $18.60 |